Truemeds is telehealth has closed its series B funding round at $22 million led by private equity fund Westbridge Capital. Also, the latest funding saw participation from existing investors, which includes InfoEdge Ventures, Asha Impact and IAN Fund. New and existing investors overvalue the subscription. This fund can be utilized to accelerate the growth in the untapped domestic market and expand its coverage across the country.

• HCL Tech Shares Gain 2% on Partnering Up with Strategy 
• Shares of Shriram Pistons skyrocketed 9% on Acquiring Antolin Lighting
• Stocks in Focus: Lloyds Engineering, SEAMEC, RailTel, and Others
• Overnight Stock Market Movements: Key Developments 
• Stocks Under F&O Ban: Bandhan Bank, and Others

Ex-Abbott executives Akshat Nayyar and Dr Kunal Wani are the founders of Truemeds, which witnessed phenomenal growth in the last two years due to strong product-market fit and massive organic demand.

According to the statement of Akshat Nayyar, Co-founder & CEO of Truemeds, “India is one of the very few markets where we have pseudo-categorization of medicines in branded and generic-generic to create different price tiers between them. Ninety-five per cent of the drugs sold in India are off-patent (thus technically generics). There is no difference between generics and branded drugs.”